Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Asheville, NC
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Durham, NC
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Cincinnati, OH
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Cleveland, OH
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Philadelphia, PA
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Providence, RI
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Memphis, TN
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Nashville, TN
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Austin, TX
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Fort Worth, TX
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Norfolk, VA
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Seattle, WA
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Morgantown, WV
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Morgantown, WV
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Miliwaukee, WI
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Miliwaukee, WI
Click here to add this to my saved trials
Full Day and Night Closed-Loop With DiAs Platform
Full Day and Night Closed-Loop With DiAs Platform
Status: Enrolling
Updated:  11/9/2015
Stanford University
mi
from
Stanford, CA
Full Day and Night Closed-Loop With DiAs Platform
Full Day and Night Closed-Loop With DiAs Platform
Status: Enrolling
Updated: 11/9/2015
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Full Day and Night Closed-Loop With DiAs Platform
Full Day and Night Closed-Loop With DiAs Platform
Status: Enrolling
Updated:  11/9/2015
University of Virginia, Center for Diabetes Technology
mi
from
Charlottesville, VA
Full Day and Night Closed-Loop With DiAs Platform
Full Day and Night Closed-Loop With DiAs Platform
Status: Enrolling
Updated: 11/9/2015
University of Virginia, Center for Diabetes Technology
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated:  11/9/2015
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated: 11/9/2015
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
Click here to add this to my saved trials
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated:  11/9/2015
University of Colorado Denver
mi
from
Aurora, CO
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated: 11/9/2015
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated:  11/9/2015
University of Colorado Hospital
mi
from
Aurora, CO
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated: 11/9/2015
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated:  11/9/2015
University Hospital, the University of Colorado Health Sciences Center
mi
from
Denver, CO
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated: 11/9/2015
University Hospital, the University of Colorado Health Sciences Center
mi
from
Denver, CO
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Birmingham, AL
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Peoria, AZ
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Peoria, AZ
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tucson, AZ
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Escondido, CA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Escondido, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
La Jolla, CA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Los Angeles, CA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Los Banos, CA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Los Banos, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Monterey, CA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Monterey, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Palm Springs, CA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Pasadena, CA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Pasadena, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Redondo Beach, CA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Redondo Beach, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
San Mateo, CA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
San Mateo, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tarzana, CA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tarzana, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tustin, CA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tustin, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Denver, CO
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Denver, CO
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Golden, CO
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Golden, CO
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Boynton Beach, FL
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
DeLand, FL
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
DeLand, FL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Miami, FL
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Miami, FL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Orange Park, FL
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Orange Park, FL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Plantation, FL
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Plantation, FL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tampa, FL
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
West Palm Beach, FL
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Dunwoody, GA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Dunwoody, GA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Arlington Heights, IL
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Chicago, IL
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Wichita, KA
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Wichita, KA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated:  11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Crestview Hills, KY
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)
Status: Enrolling
Updated: 11/10/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Crestview Hills, KY
Click here to add this to my saved trials